Incyte Corporation (Incyte) is a drug discovery and development company focused on developing small molecule drugs to treat serious unmet medical needs. The Company has a pipeline with programs focused primarily in the areas of oncology and inflammation. Its priority programs involve its janus kinase (JAK) inhibitors, which include oral INCB18424 for hematologic and oncology indications, and oral INCB28050 for chronic inflammatory and autoimmune diseases. Oral INCB18424 is in Phase III development as a treatment for myelofibrosis, the advanced of the myeloproliferative neoplasms and Phase II development for two of the other myeloproliferative neoplasms, polycythemia vera and essential thrombocythemia. Oral INCB28050 is in Phase II development for rheumatoid arthritis. The Company’s pipeline includes compounds in various stages of development, primarily in the areas of oncology and inflammation.
Research Alerts:
Receive alerts on the latest reports on Incyte Corporation
Subscribe to Research Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
